Since
2017
The Netherlands
Imaging
TRL 4

Challenge

Bladder cancer is the 5th most prevalent cancer worldwide, and the most expensive cancer from diagnosis to death. Every year over 340.000 new patients are diagnosed worldwide. Current diagnostic methods are inadequate, as the urologist has to base his decision on incomplete visual information. This leads to the fact that 30% of the surgeries performed are unnecessary, and in 30% of the cases tumors are missed.

Opportunity

Scinvivo’s imaging catheter provides real time, cross-sectional, in depth tissue images. Using this disrupting technology, the urologist can see what is going on beneath the bladder wall surface and provide a more accurate diagnosis. Expenses will decrease as unnecessary surgeries are prevented. The catheter is in the working channel of the cystoscope that is used during bladder examinations, and is an addition to this examination.

Solution

The imaging catheter works using Optical Coherence Tomography (OCT), which is a technology analogous to ultrasound, but uses photonics instead of soundwaves. Using light enables a very high resolution (1-50 μm) over a depth range of 3mm. Literature shows the benefits of using OCT in the bladder. The catheter uses innovative microelectro-mechanical-system (MEMS) mirror technology to create a laser scanner that scans the suspicious tissue.

Status

Scinvivo filed a patent on the MEMS technology and the application in a forward looking OCT-catheter. Because of the innovative MEMS technology used in our catheter, Scinvivo has a 4 years head start and a €4M advantage on companies that want to copy the product. The AMC hospital in Amsterdam has ordered the first 25 catheters for a price of 750€ apiece. Next to that, Scinvivo obtained multiple subsidies and loans.

Meet the team

Maaike-de-Jong--1024x1000

Maaike de Jong

Inventor/CTO

marijn-150x150

Marijn van Os

CEO

Roland 1 (3)

Roland Zegger

Venture Partner at NLC

Trained as a Pharmacist, he worked in several pharmaceutical companies and has broad experience in marketing and sales functions as well as general management.  As Venture Partner his focus is on building innovative companies and strengthening NLC’s abilities to bring innovations to healthcare.